SCHEMBL27119247

SCHEMBL27119247

Cn1ncc2cccc(NS(=O)(=O)c3ccc(-c4cccnc4Cl)nc3)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 10/20 0.43
▸ KMT2A Q03164 6/20 0.42
▸ MEN1 O00255 5/20 0.42
▸ TDP1 Q9NUW8 6/20 0.41
▸ GLO1 Q04760 6/20 0.41
▸ AGTR1 P30556 2/20 0.41
▸ MITF O75030 1/20 0.41
▸ S1PR4 O95977 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ CKS1B P61024 1/20 0.41
▸ SKP2 Q13309 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ CCR4 P51679 1/20 0.40
▸ PIK3CA P42336 1/20 0.39
▸ G6PD P11413 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30846347 1.00 SLC40A1 (0.43) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27118022 0.90 SLC40A1 (0.45) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL30846219 0.90 SLC40A1 (0.45) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27118281 0.87 SLC40A1 (0.44) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27119249 0.87 SLC40A1 (0.41) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL30846290 0.87 SLC40A1 (0.41) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL30846320 0.87 SLC40A1 (0.44) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL30846443 0.85 SLC40A1 (0.48) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27118016 0.85 SLC40A1 (0.48) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27118385 0.85 SLC40A1 (0.44) SLC40A1KMT2AMEN1TDP1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044344-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150365-A1 PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B SLC40A1 816/4885KMT2A 974/4885MEN1 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback